Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 28, 2025
Distillery Therapeutics

De novo-designed antivenom for snakebite

BioCentury | Sep 6, 2022
Distillery Therapeutics

Targeting three thalamic circuits in Parkinson's disease

BioCentury | Jun 6, 2022
Deals

Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger

Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Oct 18, 2021
Regulation

New nasal spray option for dry eye as Oyster Point wins FDA nod

Oyster Point’s Tyrvaya offers dosing advantage over artificial tears
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin aims to tamp down neuron excitability with its conditionally active ion channels
BioCentury | Oct 16, 2019
Product Development

Relmada data offer hope of safer option for depression

Relmada’s depression therapy may avoid the psychotomimetic effects of J&J’s esketamine, enabling at-home use
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

With four liquidity events already from its first fund, Vida wants its second to deliver cures
Items per page:
1 - 10 of 50